2 completed, 1 recruiting, 1 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow INCB000928: new trials by email Literature Review of INCB000928 trials Research Report on INCB000928
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva INCB000928, Placebo - Fibrodysplasia Ossificans Progressiva (FOP) | Phase 2 | Recruiting | Incyte Corporation | 98 | 2022-05-05 | 2026-10-22 |
| Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis INCB000928 - Renal Impairment, Hemodialysis | Phase 1 | Completed | Incyte Corporation | 48 | 2021-12-14 | 2023-05-15 |
| To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma INCB000928 - Myelodysplastic Syndromes, Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 22 | 2021-08-19 | 2025-10-22 |
| INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders INCB000928, ruxolitinib - Anemia, Post-essential Thrombocythemia Myelofibrosis | Phase 1 / Phase 2 | Completed | Incyte Corporation | 84 | 2021-03-19 | 2026-10-01 |
Anemia (2) · Myositis Ossificans (2) · Kidney Failure, Chronic (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Ossification, Heterotopic (1) · Renal Insufficiency (1)
United States (4) · France (3) · Italy (3) · Canada (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Brazil (1) · Chile (1) · China (1) · Germany (1) · Japan (1) · Mexico (1) · Netherlands (1) · New Zealand (1)
Amanda McBride, MD (2) · Ekatarine Asatiani, MD (1)
2023 (2)